Abstract:
:There have been great technological advances in the use of antiretroviral therapies to slow down disease progression in HIV/AIDS. Combinations of therapeutics and the use of several diagnostic methods have resulted in both declines in mortality and the occurrence of opportunistic infections. The higher costs of these therapeutics have prompted questions about the economic aspects of treatment with antiretrovirals. In this review, we provide an overview of the research that has been published on this topic and list the important outcomes and methodological issues associated with the different therapies.
journal_name
Expert Rev Pharmacoecon Outcomes Resjournal_title
Expert review of pharmacoeconomics & outcomes researchauthors
Bos JM,Berg LT,Postma MJdoi
10.1586/14737167.1.1.77subject
Has Abstractpub_date
2001-10-01 00:00:00pages
77-84issue
1eissn
1473-7167issn
1744-8379journal_volume
1pub_type
杂志文章abstract::This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized static model of two markets (North and South) to analyse the conditions un...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/14737167.2014.927315
更新日期:2014-10-01 00:00:00
abstract::A review was undertaken to identify relevant and appropriate heath-utility estimates for patients with atrial fibrillation who had stroke and to appraise them against the published requirements for several countries' Health Technology Assessment agencies: Australia (Pharmaceutical Benefits Advisory Committee), Canada ...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/erp.09.62
更新日期:2009-12-01 00:00:00
abstract::Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a P...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2014.940902
更新日期:2014-10-01 00:00:00
abstract::Social Security Disability Insurance provides cash benefits to disabled workers and certain others under the age of 65 years. These individuals become eligible for Medicare 24 months after Social Security Disability Insurance cash benefits start. In 2001, 13.9% of Medicare's approximately 40 million beneficiaries were...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.6.3.261
更新日期:2006-06-01 00:00:00
abstract::The European Quality of Life-5 Dimensions Questionnaire (EQ-5D) is the most common instrument to value health outcomes under the patient's perspective. Several studies have investigated whether observed changes are meaningful to patients, using a variety of approaches to estimate the minimum clinically important diffe...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/14737167.2014.894462
更新日期:2014-04-01 00:00:00
abstract::Influenza, the seventh leading cause of death in the USA, accounts for 35,000 deaths and over 200,000 hospitalizations annually in that country alone. Recent advances in influenza vaccines, diagnosis and treatment have created numerous options for practicing clinicians, as well as economic opportunities for the makers...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.5.2.141
更新日期:2005-04-01 00:00:00
abstract:BACKGROUND:Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U....
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2018.1476142
更新日期:2018-08-01 00:00:00
abstract:BACKGROUND:Although Health Technology Assessment (HTA) is increasingly used to support evidence-based decision-making in health care, several barriers and facilitators for the use of HTA have been identified. This best-worst scaling (BWS) study aims to assess the relative importance of selected barriers and facilitator...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2017.1375407
更新日期:2018-04-01 00:00:00
abstract::This review was designed to explore and review the range of patient-reported outcomes used to assess people with epilepsy. Literature searches were conducted through EMBASE.com and supplemented with hand searching of relevant articles. References obtained through hand searches were compared with EMBASE.com citations u...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.7.4.373
更新日期:2007-08-01 00:00:00
abstract::Economists' approaches to priority setting focus on the principles of opportunity cost, marginal analysis and choice under scarcity. These approaches are based on the premise that it is possible to design a rational priority setting system that will produce legitimate changes in resource allocation. However, beyond is...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/erp.10.66
更新日期:2010-10-01 00:00:00
abstract::It is well accepted that psoriasis has a profound impact on the life of the patient. Moderate-to-severe psoriasis frequently requires phototherapy or aggressive systemic treatment; unfortunately these treatments have major limitations. New biologic treatments are now available that offer distinct safety advantages and...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.4.5.573
更新日期:2004-10-01 00:00:00
abstract:AIMS:To estimate the direct and indirect costs associated with disability due to multiple sclerosis (MS) in Poland. METHODS:Recently a cost-of-illness study was conducted in the Czech Republic, involving 909 patients with different levels of disability (the COMS study). Data on resource use from this trial was extrapo...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2014.906305
更新日期:2014-06-01 00:00:00
abstract:AIMS:To quantify the relationship between the timing of gastroesophageal reflux disease (GERD) symptoms and the burden of illness. PATIENTS & METHODS:Data from the 2010 National Health and Wellness Survey were used. Regression analyses compared non-GERD controls with GERD patients with diurnal symptoms, nocturnal symp...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/erp.11.72
更新日期:2011-12-01 00:00:00
abstract::A systematic review was conducted of the full economic evaluations of the cost-effectiveness of peginterferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin (RBV) in the treatment of chronic hepatitis C (CHC). A total of 439 references were screened and 11 studies were included. The studies employed decision analytic Markov...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.7.6.577
更新日期:2007-12-01 00:00:00
abstract::Introduction: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality worldwide. The chronic progressive disease is accompanied by a high loss of health-related quality of life (HRQoL). The available drugs usually only have symptomatic effects; therefore, non-pharmacological therapies are ...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2020.1734455
更新日期:2020-02-01 00:00:00
abstract::Recently, the person tradeoff method has received much attention because it directs one to value health improvements of those other than one's self. As a result, several researchers have suggested that the person tradeoff measures preferences in pharmaceutical and health economic analysis more accurately than the stan...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.5.6.677
更新日期:2005-12-01 00:00:00
abstract:BACKGROUND:Four hurdles associated with economic evaluations in welfare interventions were identified and discussed in a previous published literature review. These hurdles include (i) 'Ignoring the impact of condition-specific outcomes', (ii) 'Ignoring the impact of QoL externalities', (iii) 'Calculation of costs from...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2017.1282316
更新日期:2017-08-01 00:00:00
abstract::Adenosine and dipyridamole are coronary vasodilators used in nuclear imaging. The acquisition cost of adenosine is four to ten times higher than dipyridamole. Data suggest comparable sensitivity, although specificity may be lower with dipyridamole. While side effect profiles are similar, fewer patients who receive ade...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2.6.555
更新日期:2002-12-01 00:00:00
abstract:OBJECTIVES:We examined the cost-effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations. STUDY DE...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2015.978292
更新日期:2015-04-01 00:00:00
abstract::Osteoarthritis is the single most important cause of disability and limitation of activity of elderly people in the UK. Although joint replacement is now commonplace for hips and increasingly so for knees, pharmacological management continues to be important. In this context, it is necessary to identify valid and acce...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2.4.337
更新日期:2002-08-01 00:00:00
abstract:OBJECTIVES:This cross-sectional study examined the prevalence and burden of major depressive disorder (MDD) among adults in urban China. METHODS:Data were included from the 2012 China National Health and Wellness Survey. Respondents self-reporting physician diagnosis of depression and screening positive for MDD (Patie...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2016.1102062
更新日期:2016-06-01 00:00:00
abstract::Interest is rising in measuring subjective health outcomes, such as treatment outcomes that are not directly quantifiable (functional disability, symptoms, complaints, side effects and health-related quality of life). Health economists in particular have applied probabilistic choice models in the area of health evalua...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/erp.12.85
更新日期:2013-02-01 00:00:00
abstract::The prevalence of multiple chronic conditions (MCC) is increasing among individuals of all ages. MCC are associated with poor health outcomes. The presence of MCC has profound healthcare utilization and cost implications for public and private insurance payers, individuals, and families. Investigators have used a vari...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/14737167.2015.1091730
更新日期:2015-01-01 00:00:00
abstract:OBJECTIVES:Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. METHODS:A Markov model was constructed to simulate the progression in a cohort of patients with moderate to severe UC. The perspective chosen was National ...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2018.1411193
更新日期:2018-06-01 00:00:00
abstract:AIM:To review and compare methods for indirect comparison of aflibercept and ranibizumab in patients with diabetic macular edema. METHODS:Post-stratification, inverse probability weighting based on simulated data, weight optimization, and regression model techniques were used to compare pooled individual patient-level...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,meta分析
doi:10.1586/14737167.2016.1165609
更新日期:2016-12-01 00:00:00
abstract:INTRODUCTION:For optimum results from pharmacological management of overactive bladder, adherence to prescribed medication is required. Overactive bladder treatment has been compromised by low adherence and persistence to medications, losing many people who might benefit from treatment and exposing them to unnecessary ...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1080/14737167.2016.1203258
更新日期:2016-08-01 00:00:00
abstract::We surveyed US-based leaders in health economics and outcomes research (HEOR) departments in drug and device companies to examine their views on the state of the field. We created a questionnaire that was emailed to 123 US-based senior HEOR professionals at 54 companies. Of the 123 recipients, 74 (60%) completed the s...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2013.838027
更新日期:2013-10-01 00:00:00
abstract::Smoking cessation is the only strategy that has shown a lasting reduction in the decline of lung function in patients with chronic obstructive pulmonary disease. This study aims to evaluate the cost-effectiveness of smoking cessation interventions in patients with chronic obstructive pulmonary disease, to assess the q...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/14737167.2015.1001976
更新日期:2015-04-01 00:00:00
abstract::Differential item functioning (DIF) analyses are used to determine whether certain groups respond differently to a particular item of a test or questionnaire; however, these do not explain the reasons for observed response differences. Many studies have used external reviews of items, sometimes using blinded reviewers...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/erp.10.22
更新日期:2010-06-01 00:00:00
abstract::Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyze the efficacy of antiparkinson drugs currently available in Latin America. A s...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/14737167.2016.1135740
更新日期:2016-01-01 00:00:00